Myoridge
Kobe, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Japanese biotech developing optimized serum-free cell culture media and process solutions for regenerative medicine and cell therapy manufacturing.
Regenerative MedicineOncology
Technology Platform
A proprietary library of media components and formulation expertise used to design and optimize serum-free, functional cell culture media for specific cell types like MSCs, T-cells, and iPSC-derived cells.
Opportunities
Growth is driven by the expanding global cell therapy market's need for optimized, serum-free, and GMP-compliant media, and by forming deep partnerships with therapy developers for process development.
Risk Factors
Revenue is dependent on the success and scale-up of client cell therapy programs; faces competition from large, established media suppliers with greater resources and global reach.
Competitive Landscape
Competes with large life science tools companies (e.g., Thermo Fisher) and specialized media firms (e.g., Fujifilm Irvine Scientific) by offering a highly customized, component-library-based design service and deep collaboration model focused on the Japanese regenerative medicine ecosystem.